Purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 (H5N1)

Key facts

Active substance
Purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 (H5N1)
Therapeutic area
Vaccines
Decision number
P/79/2009
PIP number
Purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 (H5N1)
Pharmaceutical form(s)
Emulsion and suspension for emulsion for injection
Condition(s) / indication(s)
Influenza infection caused by an influenza strain contained in the vaccine or related to a strain contained in the vaccine
Route(s) of administration
Intramuscular injection
Contact for public enquiries
GlaxoSmithKline Biologicals S.A. (UK)

E-mail: eu.paediatric-plans@gsk.com
Country: United Kingdom
Phone: +44 2089663220
Fax: +44 2089662221

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Topics

How useful was this page?

Add your rating